Genmab — Juni 2018

[E_L]

most of his net worth is in this company, i find it hard to believe he would contemplate his own sales network if the did not believe part of his pipeline would succeed

[E_L]

but his horizon is much longer as most here...

[Plimsoller]

His horizon is hopefully the same as mine 3 years.

[StockBull]

Jvdw har indikeret 9b usd i mm og 13 hvis dara virker i solid

[StockBull]

Uhttps://seekingalpha.com/news/3245374-genmab-chief-says-cancer-med-darzalex-achieve-peak-sales-9b

[Helge_LarsenPI-redaktør]

Tak Stock bull. Jeg huskede de 13, men ikke at det var med solide.

[JKY_VH]

Enig Helge 13:05, det ville være værre

[E_L]

EP Vantage Asco 2018 – Good might not good enough for Bluebird http://epvantage.com/Universal/View.aspx?type=Story&id=792564&isEPVantage=yes

[E_L]

should monoclonal antibodies be used at first relapse in myeloma? https://twitter.com/SurbhiSidana/status/1002978022889226241

[E_L]

https://twitter.com/tanyawildes/status/1002985832322650112

[GeorgeBest]

https://twitter.com/tanyawildes/status/1002985832322650112?s=21

[Legolas23]

70-80% as far 20bn marked ?

[GeorgeBest]

https://twitter.com/adamfeuerstein/status/1002712330961145857?s=21

[Plimsoller]

GB. Ved du om det er et gennemgående tema mht. både patientudvælgelse og fremlæggelse af resultater i forhold til Bluebird?

[GeorgeBest]

Nej

[Plimsoller]

Ok. Synes blot at jeg herinde har set noget angår de

[Plimsoller]

angående patientudvælgelsen før.

[GeorgeBest]

Hvad jeg får ud af at læse på Twitter, er at bb2121 er rigtig godt når alt andet inclusive dara er prøvet. Altså mindst 5-6 linie behandling. Patienterne har her ikke andre muligheder end CAR-T.

[Plimsoller]

Ok. Tak.

[E_L]

i remember reading that they have been very carefull in selecting their patients, also they are relatively young, the selection process apparantly took very long; is that what you were asking @
Plimsoller ?